Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL at screening~* HCV treatment-naive, as defined as no prior exposure to any interferon (IFN) or other approved or experimental HCV-specific direct-acting antiviral agent; OR HCV treatment-experienced with medical records that include sufficient detail of prior IFN-based treatment to allow for categorization of prior response as either intolerant, non-responder, or experienced viral breakthrough or relapse.~* Genotype 1 HCV at screening~* HCV infection documented by anti-HCV antibody test, genotyping test, or liver biopsy~Key Exclusion Criteria:~* Pregnant or nursing female~* Chronic liver disease of a non-HCV etiology~* Current or prior history of any clinically-significant illness (other than HCV)~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF (Type: EXPERIMENTAL): Treatment-experienced and treatment-naive participants will receive LDV/SOF for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).